These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 27268124)

  • 21. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
    Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP
    Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930
    [No Abstract]   [Full Text] [Related]  

  • 22. [Evaluation of clinical characteristics, MYD88(L265P) mutation, CXCR4(WHIM) mutation and prognosis in Waldenström macroglobulinemia: A single center retrospective study of 93 patients].
    Cao XX; Meng Q; Cai H; Mao YY; Duan MH; Zhu TN; Zhang W; Han B; Zhuang JL; Cai HC; Chen M; Feng J; Han X; Zhang Y; Yang C; Zhang L; Zhou DB; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):494-498. PubMed ID: 28655092
    [No Abstract]   [Full Text] [Related]  

  • 23. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.
    Hunter ZR; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Manning RJ; Tripsas C; Patterson CJ; Sheehy P; Treon SP
    Blood; 2014 Mar; 123(11):1637-46. PubMed ID: 24366360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.
    Treon SP; Xu L; Guerrera ML; Jimenez C; Hunter ZR; Liu X; Demos M; Gustine J; Chan G; Munshi M; Tsakmaklis N; Chen JG; Kofides A; Sklavenitis-Pistofidis R; Bustoros M; Keezer A; Meid K; Patterson CJ; Sacco A; Roccaro A; Branagan AR; Yang G; Ghobrial IM; Castillo JJ
    J Clin Oncol; 2020 Apr; 38(11):1198-1208. PubMed ID: 32083995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.
    Kapoor P; Paludo J; Ansell SM
    Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Waldenström macroglobulinemia.
    Treon SP; Hunter ZR; Castillo JJ; Merlini G
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):945-70. PubMed ID: 25212891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of MYD88 L265P mutations in formalin-fixed and decalcified BM biopsies from patients with lymphoplasmacytic lymphoma.
    Capaldi IB; May AM; Schmitt-Graeff A; Follo M; Aumann K; Kayser G; Perazzo JC; Werner M; Fisch P
    Exp Mol Pathol; 2014 Aug; 97(1):57-65. PubMed ID: 24842316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.
    Hamadeh F; MacNamara SP; Aguilera NS; Swerdlow SH; Cook JR
    Mod Pathol; 2015 Apr; 28(4):564-74. PubMed ID: 25216226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations.
    King RL; Gonsalves WI; Ansell SM; Greipp PT; Frederick LA; Viswanatha DS; He R; Kyle RA; Gertz MA; Kapoor P; Morice WG; Howard MT
    Am J Clin Pathol; 2016 Jun; 145(6):843-51. PubMed ID: 27329639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas.
    Gachard N; Parrens M; Soubeyran I; Petit B; Marfak A; Rizzo D; Devesa M; Delage-Corre M; Coste V; Laforêt MP; de Mascarel A; Merlio JP; Bouabdhalla K; Milpied N; Soubeyran P; Schmitt A; Bordessoule D; Cogné M; Feuillard J
    Leukemia; 2013 Jan; 27(1):183-9. PubMed ID: 22944768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.
    Hunter ZR; Xu L; Yang G; Tsakmaklis N; Vos JM; Liu X; Chen J; Manning RJ; Chen JG; Brodsky P; Patterson CJ; Gustine J; Dubeau T; Castillo JJ; Anderson KC; Munshi NM; Treon SP
    Blood; 2016 Aug; 128(6):827-38. PubMed ID: 27301862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction.
    Jiménez C; Chillón Mdel C; Balanzategui A; Puig N; Sebastián E; Alcoceba M; Sarasquete ME; Conde IP; Corral R; Marín LA; Paiva B; Ruano M; Antón A; Maldonado R; San Miguel JF; González M; García-Sanz R
    Appl Immunohistochem Mol Morphol; 2014; 22(10):768-73. PubMed ID: 24992174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88
    Guérémy A; Boucraut J; Boudjarane J; Grapperon AM; Fortanier E; Farnault L; Gabert J; Vely F; Lacroix R; Kouton L; Attarian S; Delmont E
    J Neurol; 2024 Mar; 271(3):1320-1330. PubMed ID: 37979093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell-free DNA analysis for detection of MYD88
    Demos MG; Hunter ZR; Xu L; Tsakmaklis N; Kofides A; Munshi M; Liu X; Guerrera ML; Leventoff CR; White TP; Flynn CA; Meid K; Patterson CJ; Yang G; Branagan AR; Sarosiek S; Castillo JJ; Treon SP; Gustine JN
    Am J Hematol; 2021 Jul; 96(7):E250-E253. PubMed ID: 33819355
    [No Abstract]   [Full Text] [Related]  

  • 35. TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.
    Gustine JN; Tsakmaklis N; Demos MG; Kofides A; Chen JG; Liu X; Munshi M; Guerrera ML; Chan GG; Patterson CJ; Meid K; Dubeau T; Yang G; Hunter ZR; Treon SP; Castillo JJ; Xu L
    Br J Haematol; 2019 Jan; 184(2):242-245. PubMed ID: 30183082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.
    Patkar N; Subramanian PG; Deshpande P; Ghodke K; Tembhare P; Mascarenhas R; Muranjan A; Chaudhary S; Bagal B; Gujral S; Sengar M; Menon H
    Leuk Lymphoma; 2015 Feb; 56(2):420-5. PubMed ID: 24828863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies.
    Bagratuni T; Ntanasis-Stathopoulos I; Gavriatopoulou M; Mavrianou-Koutsoukou N; Liacos C; Patseas D; Kanellias N; Migkou M; Ziogas DC; Eleutherakis-Papaiakovou E; Roussou M; Fotiou D; Terpos E; Kastritis E; Dimopoulos MA
    Leukemia; 2018 Dec; 32(12):2617-2625. PubMed ID: 30026568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.
    Varettoni M; Arcaini L; Zibellini S; Boveri E; Rattotti S; Riboni R; Corso A; Orlandi E; Bonfichi M; Gotti M; Pascutto C; Mangiacavalli S; Croci G; Fiaccadori V; Morello L; Guerrera ML; Paulli M; Cazzola M
    Blood; 2013 Mar; 121(13):2522-8. PubMed ID: 23355535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.
    Baer C; Dicker F; Kern W; Haferlach T; Haferlach C
    Leukemia; 2017 Jun; 31(6):1355-1362. PubMed ID: 27840426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Lymphoplasmacytic lymphoma accompanied by transformed diffuse large B-cell lymphoma with the MYD88
    Kida T; Tanimura A; Ono A; Matsui T; Honma K; Fujita J; Maeda T; Shibayama H; Oritani K; Morii E; Kanakura Y
    Rinsho Ketsueki; 2017; 58(2):155-160. PubMed ID: 28321094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.